Receptor and Nonreceptor-Mediated Organ-Specific Toxicity of Di(2-ethylhexyl)phthalate (DEHP) in Peroxisome Proliferator-Activated Receptorα-Null Mice

Abstract

The peroxisome proliferator-activated receptora (PPARα) is the mediator of the biological effects of peroxisome proliferators through control of gene transcription. To determine if the toxic effects of di(2-ethylhexyl)phthalate (DEHP) are mediated by PPARα, we examined its effect in PPARα-null mice. Male Sv/129 mice, PPARα-null (–/–) or wild-type (+/+) were fed ad libitum either a control diet or one containing 12,000 ppm DEHP for up to 24 wk. Significant body weight loss and high mortality was observed in (+/+) mice fed DEHP. By 16 wk, all DEHP-fed (+/+) mice had died of cystic renal tubular disease. In contrast, the (–/–) mice fed DEHP had no changes in body weight until later in the study nor increased mortality. Histologically, (+/+) mice fed DEHP had typical toxic lesions in liver, kidney, and testis while (–/–) mice fed DEHP had no toxic liver lesions but did show evidence of toxicity in kidney and testis after 4–8 wk of feeding, which progressed into moderate lesions by 24 wk. Analysis of hepatic and renal mRNAs showed a typical pleiotropic response in gene expression in the DEHP-fed (+/+) mice that was absent in the DEHP-fed (–/ –) mice. These results provide evidence that PPARα mediates the subacute-chronic toxicity of DEHP in liver, kidney, and testis. However, because (-/–) mice did develop toxic lesions in kidney and testis, DEHP can also act through PPARα-independent pathways in mediating renal and testicular toxicity.

Keywords

Knockout mice peroxisomal proliferator liver peroxisomal proliferator activated receptor di(2-ethylhexyl)phthalate (DEHP)kidney cystic kidneys

References

1. Auwerx J (1992). Regulation of gene expression by fatty acids and fibric acid derivatives: An integrative role for peroxisome proliferator activated receptors. Horm. Res. 38: 269–277.

2. Castelein H , Gulick T , Declercq PE , Mannaerts GP , Moore DD , and Baes BI (1994). The peroxisome proliferator activated receptor regulates malic enzyme gene expression. J. Biol. Chem. 269: 26754–26758.

3. Chen F , Law SW , and O'Malley BW (1993). Identification of two mPPAR related receptors and evidence for the existence of five subfamily members. Biophys. Res. Commun. 196: 671–677.

4. Devchand PR , Keller H , Peters JM , Vazquez M , Gonzalez FJ , and Wahli W (1996). The PPARα-leukotriene B4 pathway to inflammation control. Nature 384: 39–43.

5. Elcombe CR and Mitchell AM (1986). Peroxisome proliferation due to di(2-ethylhexyl)phthalate (DEPH): Species differences and possible mechanisms. Environ. Health Perspect. 70: 211–219.

6. Fahimi HD , Baumgart E , Beier K , Pill J , Hartig F , and Volkl A (1993). Ultrastructural and biochemical aspects of peroxisome proliferation and biogenesis in different mammalian species. In: Peroxisomes: Biology and Importance in Toxicology and Medicine B, G Gibson and B Lake (eds). Taylor and Francis Ltd., London, pp. 395–424.

7. Forman BM , Chen J , and Evans RM (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA 94: 4312–4317.

8. Gearing KL , Crickmor A , and Gustafsson J-A (1994). Structure of the mouse peroxisome proliferator activated receptor alpha gene. Biochem. Biophys. Res. Commun. 199: 225–263.

9. Grasso P (1993). Hepatic changes associated with peroxisome proliferation. In: Peroxisomes: Biology and Importance in Toxicology and Medicine, G Gibson and B Lake (eds). Taylor and Francis Ltd., London, pp. 639–651.

10.

10. Green S (1995). PPAR: A mediator of peroxisome proliferator action. Mutat. Res. 333: 101–109.

11.

11. Gulick T , Cresci S , Caira T , Moore DD , and Kelly DP (1994). The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc. Natl. Acad. Sci. USA 91: 11012–11016.

12.

12. Huber WW , Grasl-Kraupp B , and Schulte-Hermann R (1996). He-patocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk. Crit. Rev. Toxicol. 26: 365–481.

13.

13. Keller H , Mahfoudi A , Dreyer C , Hihi AK , Medin J , Ozato K , and Wahli W (1993). Peroxisome proliferator-activated receptors and lipid metabolism. Ann. N.Y. Acad. Sci. 684: 157–173.

14.

14. Kliewer SA , Forman BM , Blumberg B , Ong ES , Borgmeyer U , Mangelsdorf DJ , Umesono K , and Evans RM (1994). Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA 91: 7355–7359.

15.

15. Kliewer SA , Sundseth SS , Jones SA , Brwon PJ , Wisely GB , Koble CS , Devchand P , Wahli W , Willson TM , Lenhard JM , and Lehmann JM (1997). Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA 94: 4318–4323.

16.

16. Lee SS-T , Pineau T , Drago J , Lee EF , Owens JW , Kroetz DL , Fernandez-Salguero PM , Westphal H , and Gonzalez FJ (1995). Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 12: 3012–3022.

17.

17. National Cancer Institute/National Toxicology Program (1981). NTP Technical Report on the Carcinogenesis Assay of Di-(2-ethyl-hexyl) phthalate. CAS No. 117-81-7, NTP-80-37. DHHS Publication No. (NIH) 81-1773.

18.

18. Peters JM , Zhou U-C , Ram PA , Lee SST , Gonzalez FJ , and Wax-man DJ (1996). Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrostcrone-3β-sulfate. Mol. Pharmacol. 50: 67–74.

19.

19. Reddy JK and Lalwani ND (1983). Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit. Rev. Toxicol. 12: 1–58.

20.

20. Risdon G , Kumar V , and Bennet M (1991). Differential effects of dehydroepiandrosterone (DHEA) on murine lymphopoiesis and myelopoiesis. Exp. Hematol. 19: 128–131.

21.

21. Schoonjan K , Staels B , and Auwerx J (1996). The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1302: 93–109.

22.

22. Sher T , Yi H-F , McBride W . and Gonzalez FJ (1993). cDNA cloning, chromosomal mapping, and functional characterization of the hman peroxisome proliferator activated receptor. Biochemistry 32: 5598–5604.

23.

23. Tugwood JD , Issemann I , Anderson RG , Bundell KR , MePheat WL , and Green S (1992). The mouse peroxisome proliferator activated receptor recognizes response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11: 433–439.

24.

24. Ward JM , Diwan BA , Ohshima M , Hu H , Schuller HM , and Rice JM (1986). Tumor-initiating and promoting activities of di(2-ethyl-hexyl) phthalate in vivo and in vitro. Environ. Health Perspect. 65: 279–291.

25.

25. Woodward KN (1990). Phthalate esters, cystic kidney disease in animals and possible effects in human health: A review. Hum. Exp. Toxicol. 9: 397–401.